Physician profile
Brian E Tschida
NPI 1851440135
$1,259.11
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $203 · 2021: $444 · 2022: $198.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $311.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.63 | 2019-2021 | |
| Zoll Respicardia, INC. | $183.23 | 2021 | |
| Emd Serono, INC. | $89.44 | 2019-2020 | |
| Amgen INC. | $85.31 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $71.88 | 2019-2022 | |
| Abbvie INC. | $57.82 | 2022 | |
| Kyowa Kirin, INC. | $42.83 | 2021-2022 | |
| Biogen, INC. | $37.93 | 2019-2020 | |
| Genentech USA, INC. | $29.62 | 2019-2021 | |
| Zogenix INC. | $28.21 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.36 | 2021 | |
| Csl Behring | $21.67 | 2022 | |
| Ge Healthcare | $19.44 | 2020 | |
| Adamas Pharmaceuticals, INC. | $16.09 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $14.08 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.56 | 2022 | |
| Harmony Biosciences LLC | $12.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Tschida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.